Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPINEC: Nivolumab +/- Ipilimumab in Refractory Neuroendocrine Carcinoma
NCT03591731Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Countries
- 1
- Sponsor
- IFCT
- Modality
- Monoclonal Antibodies
- Drugs
- nivolumabipilimumab
- Conditions
- neuroendocrine carcinoma (NEC)
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in neuroendocrine carcinoma (NEC), sponsored by IFCT. Started Jan 2019; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
Neuroendocrine tumors of the lung include the small cell carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC) and represent 20% of lung cancer. One of the only studies reported to date is reporting on a progression-free survival (PFS) and overall survival (OS) of 5.2 months and 7.7 months, respectively.
Poorly differentiated gastroentero-pancreatic neuroendocrine carcinomas (GEP-NEC) represent a small sub-group of digestive NENs, according to the studies, 7 to 21% of patients. However, their prognosis is more negative, with the 5-year survival at less than 20%.
Many Phase III…
Beyond the preview
Go deeper on NCT03591731.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591731.